City Therapeutics Secures $99.5M Series B for RNAi

City Therapeutics raised $99.5 million in Series B to advance RNAi therapies outside the liver. The funding supports Phase 1 trials for CITY-FXI and clinical entry of CITY-RBP4. The platform uses engineered RNAi triggers paired with precision ligands to target non-liver cells. Investors include Viking Global, Sofinnova, Casdin Capital, and NYBC Ventures.